home / stock / isee / isee news


ISEE News and Press, IVERIC bio Inc. From 05/01/23

Stock Information

Company Name: IVERIC bio Inc.
Stock Symbol: ISEE
Market: NYSE
Website: ivericbio.com

Menu

ISEE ISEE Quote ISEE Short ISEE News ISEE Articles ISEE Message Board
Get ISEE Alerts

News, Short Squeeze, Breakout and More Instantly...

ISEE - Wall Street Breakfast Podcast: JPMorgan To Acquire First Republic Bank

2023-05-01 07:16:39 ET Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify First Republic Bank ( FRC ) is seized, will be sold to JPMorgan. Nornickel ( NILSY ) board recommends no dividend for first time since 20...

ISEE - Astellas to acquire IVERIC Bio for $5.9B

2023-05-01 04:41:56 ET Astellas Pharma ( OTCPK:ALPMY ) through its subsidiary, Berry Merger Sub will acquire IVERIC Bio ( NASDAQ: ISEE ) for $40 per share in cash for a total equity value of ~$5.9B. In the acquisition, Iveric Bio will become an indirectly who...

ISEE - Astellas Pharma agrees to buy Iveric Bio for $5.9 Billion

2023-04-30 21:24:34 ET Astellas Pharma ( OTCPK:ALPMF ) agreed to acquire Iveric Bio ( NASDAQ: ISEE ) for $5.9 billion to add ophthalmology capabilities to the Japanese pharmaceutical giant. Under the agreement, Astellas ( OTCPK:ALPMF ) agreed to purchase Iveric...

ISEE - Astellas Enters into Definitive Agreement to Acquire Iveric Bio

Astellas Enters into Definitive Agreement to Acquire Iveric Bio PR Newswire -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023 - ...

ISEE - Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023 - -Acquisition advances Astellas’ Primary Focus on “Blindness & Regeneration &...

ISEE - Second Quarter Outlook For Biotech Stocks

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

ISEE - Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting

- Post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol (ACP) was correlated with reduced geographic atrophy (GA) growth - - Post-hoc time-to-event analyses signal fewer patients receiving ...

ISEE - RIG, PR nd CEI are among pre market gainers

2023-04-03 08:18:23 ET Indonesia Energy Corporation  ( NYSE: INDO ) +40% . New Concept Energy ( GBR ) +32% . U.S. Energy  ( USEG ) +29% . Guardforce AI  ( GFAI ) +29% . Barnwell Industries ( BRN ) +22% . Housto...

ISEE - Apellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy Market

2023-03-24 14:37:39 ET Summary Apellis Pharmaceuticals received FDA approval for Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration. Over 1 million people in the US and 5 million worldwide are affected by GA, providing a sig...

ISEE - Iveric Bio: ACP Advances As GATHER Results Continue To Impress

2023-03-23 14:37:16 ET Summary Iveric Bio has a promising pipeline of products, including its complement C5 inhibitor, avacincaptad pegol (ACP), which has achieved impressive results in phase 3 clinical trials. The company's recent post-hoc analysis from its GATHER clinical trial ...

Previous 10 Next 10